Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia

• Phase: Phase 2

Details

• Lead Sponsor: UCB Pharma
• Treatments: Antipsychotic Agents; Etiracetam; Levetiracetam; Piracetam

Criteria

Inclusion Criteria:

• Subjects between ages 18 and 80 years

• Subjects must have a diagnosis of stable axis I psychiatric disorder at least 6 months prior to screening

• Subjects must have a stable neuroleptic-induced tardive dyskinesia at least 1 month prior to screening and meet tardive dyskinesia severity criteria

• Subjects must have used antipsychotics for at least 6 cumulative months, and, be on a stable dose for 1 month prior to screening

Exclusion Criteria:

• Presence of any axis II condition within 6 months prior to screening

• Huntington´s disease, idiopathic dystonia, Wilson´s disease, Sydenham´s chorea, thyroid dysfunction, spontaneous dyskinesia

• Start of drugs-other than neuroleptics- that can cause dyskinesia

• Presence of additional major disease such as cardiac, renal or hepatic dysfunction or terminal illness